Context: Current knowledge on gonadal function in congenital adrenal hyperplasia (CAH) is mostly limited to single-center/country studies enrolling small patient numbers. Overall data indicate that gonadal function can be compromised in men with CAH. Objective: To determine gonadal function in men with CAH within the European 'dsd-LIFE' cohort. Design: Cross-sectional clinical outcome study, including retrospective data from medical records. Methods: Fourteen academic hospitals included 121 men with CAH aged 16-68 years. Main outcome measures were serum hormone concentrations, semen parameters and imaging data of the testes. Results: At the time of assessment, 14/69 patients had a serum testosterone concentration below the reference range; 7 of those were hypogonadotropic, 6 normogonadotropic and 1 hypergonadotropic. In contrast, among the patients with normal serum testosterone (55/69), 4 were hypogonadotropic, 44 normogonadotropic and 7 hypergonadotropic. The association of decreased testosterone with reduced gonadotropin concentrations (odds ratio (OR) = 12.8 (2.9-57.3)) was weaker than the association between serum androstenedione/testosterone ratio ≥1 and reduced gonadotropin concentrations (OR = 39.3 (2.1-732.4)). Evaluation of sperm quality revealed decreased sperm concentrations (15/39), motility (13/37) and abnormal morphology (4/28). Testicular adrenal rest tumor (TART)s were present in 39/80 patients, with a higher prevalence in patients with the most severe genotype (14/18) and in patients with increased current 17-hydroxyprogesterone 20/35) or androstenedione (12/18) serum concentrations. Forty-three children were fathered by 26/113 patients. Conclusions: Men with CAH have a high risk of developing hypothalamic-pituitary-gonadal disturbances and spermatogenic abnormalities. Regular assessment of endocrine gonadal function and imaging for TART development are recommended, in addition to measures for fertility protection.
Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder resulting in impaired adrenocortical steroid synthesis by several enzyme deficiencies. The most common form (>95%) is 21-hydroxylase deficiency (21OHD) with an incidence of 1:15 000, leading to glucocorticoid and often also mineralocorticoid deficiency in combination with androgen excess (1, 2) .
Reported fertility and fecundity in men with CAH on routine steroid replacement therapy range from normal to severely impaired. Fertility can be compromised due to primary (hypergonadotropic) hypogonadism or central (hypogonadotropic) hypogonadism (3, 4, 5, 6, 7, 8, 9, 10, 11) . In addition, reduced fertility and fecundity rates in CAH can be caused by psychosexual factors (4) . Central or secondary hypogonadism is defined as decreased testosterone concentrations in combination with either low or low-normal LH or FSH concentrations. In men with CAH, secondary hypogonadism is most likely caused by the suppressive effect of elevated adrenal androgens (that are aromatized to estrogens) on the hypothalamicpituitary-gonadal (HPG) axis (6) . Differentiation between gonadal and adrenal testosterone is difficult, complicating the diagnosis of hypogonadism in men with CAH. One of the commonest complications in men with CAH is the presence of testicular adrenal rest tumor (TART)s, which can cause disturbances of gonadal function, including mechanical obstruction of the seminiferous tubules. The reported prevalence of TARTs ranges between 12.5% and 94% in the populations studied (4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22) .
Until now, the data on fertility outcome in men with CAH are scarce (3, 4, 5, 6, 7, 8, 9, 10, 11) and often derived from studies with patients from a single center or country. Our aim was to study gonadal function in a large European multicenter cohort of male patients with CAH by evaluating hormone concentrations, semen parameters and TART frequency.
Subjects and methods
Subjects dsd-LIFE is a cross-sectional clinical outcome study of individuals with disorders/differences of sex development (DSD). Fourteen study centers in 6 European countries (France (n = 4), Germany (n = 4), United Kingdom (n = 1), Poland (n = 2), Sweden (n = 1) and the Netherlands (n = 2)) included former and current patients as participants from February 2014 to September 2015. In addition to DSD participants, 121 male participants with CAH (46XY karyotype) aged 16-68 years were recruited as they may face similar clinical challenges as DSD patients, including sex hormone imbalances and fertility problems, although male patients with CAH do not fit into the classification of DSD. Written informed consent was obtained from all participants and/or their parents, with assent of minors. Ethical approvals were obtained as appropriate for each country. The theoretical and methodological framework of the dsd-LIFE study have been published in detail (23) . Patients were investigated in their local treatment center. Cross-sectional data were obtained for serum hormone concentrations, semen parameters and testicular imaging. The genotype of patients with 21OHD was classified into genotype groups null, A, B, and C (24) . General patient characteristics and clinical parameters included: country of inclusion, age, age at diagnosis, CAH genotype and phenotype, socioeconomic status and obesity, as well as height, weight and BMI throughout the years (at diagnosis, 9 months old, 6 years old, Tanner stage 2, 16 years old and current age). Patients' educational levels were established according to the EU classification. We combined the standardized ES-ISCED (international standard classification of education) scale to low (ES-ISCED I = less than lower secondary and ES-ISCED II = lower secondary); medium (ES-ISCED IIIb = lower tier upper secondary; ES-ISCED IIIA = upper tier upper secondary; ES-ISCED IV = advanced vocational, subdegree) and high (ES-ISCED V1 = lower tertiary education, BA level; ES-ISCED V2 = higher tertiary education, ≥MA level). Data were collected during medical examination at study inclusion (cross-sectional) and retrieved from medical records (retrospective data).
Hormonal analysis
Blood samples were taken during day time, but mostly in the morning, before intake of the glucocorticoid medication (23) . Total testosterone, SHBG, LH, FSH, inhibin B, AMH, androstenedione, 17-hydroxyprogesterone (17OHP) concentrations and renin/plasma renin activity were measured in the local hospital laboratory and compared to local references. Values are reported in SI or international units and reported as 'below reference range', 'within reference range', 'above reference range up to twice the upper limit' and 'more than twice the upper limit of the reference range'. To increase the number of patients per category, we combined the latter 2 categories into the category 'above reference range'.
The serum androstenedione/testosterone ratio (AD/TS) was calculated and divided into normal (<0.5; interpreted as testosterone mainly of testicular origin), ≥0.5 and <1 (significant fraction of testosterone is of adrenal origin) and ≥1 (testosterone mainly of adrenal origin) as suggested by others (25) .
Semen analysis
Semen analysis was performed by the local hospital laboratory and interpreted in accordance with the 2010 World Health Organization criteria (26) , including sperm concentration (lower reference limit (LRL): 15 × 10 6 /mL), motility (LRL: 40%), morphology (LRL: 4%), vitality (LRL: 58%) and volume (LRL: 1.5 mL).
Imaging of testes
At the study visit, 68 patients (56.2%) underwent testicular ultrasound. The presence of TART at the age of 16 years was also reported retrospectively (in 30/68 patients with crosssectional TART data). In addition, retrospective data were available for 12 participants based on ultrasound findings or MRI (n = 11) and on histological findings (n = 1).
Paternity
Data about paternity and relationships were collected from the dsd-LIFE questionnaires (23) .
Medication and estimation of metabolic control in the past
Patients used different formulations of glucocorticoids, including hydrocortisone, prednisone, prednisolone and dexamethasone. Furthermore, we converted all glucocorticoid preparations to hydrocortisone equivalents, using the following factors for the glucocorticoid equivalent dose: 1 (hydrocortisone), 4 (prednisone or prednisolone), 30 (dexamethasone) and 15 (fludrocortisone) (27) . We also calculated mineralocorticoid equivalent dose using the following factors: 1 (hydrocortisone), 0.8 (prednisone or prednisolone), 0 (dexamethasone) and 200 (fludrocortisone) (27) . In addition to the serum 17OHP concentrations presented in the section hormonal analysis, we also assessed metabolic control by a subjective rating, of the local examining physician at 5 different time points: at diagnosis, at the age of 9 months, at Tanner stage 2, at age 16 years and at study inclusion, using the following scores: 'poor', 'moderate', 'good', 'excellent' or 'unknown'.
Statistical analysis
SPSS Statistics 22 (SPSS) was used for all analyses. Descriptive analyses were performed for all variables. Depending on normality, mean and 95% confidence intervals (95% CI) or median and interquartile ranges (IQR) were calculated. We compared patients with values below or above reference range to patients with normal values (within the reference range). Odds ratios (OR) with 95% CI were calculated if at least 3 cases were present in both subgroups. If any cell count in the contingency table was zero, OR and 95% CI were calculated manually by using a continuity correction (+0.5 in each cell).
Missing data were evaluated for each variable and the total number of participants in a particular analysis was reported exactly. Analysis of the variables was performed only if the number of participants was ≥25% of the total cohort of male patients with CAH.
Three patients were excluded from part of the analyses as they received testosterone substitution, which directly affects testosterone and gonadotropin concentrations. Two of these patients had data on TART available; these are described in the 'Results' section. Furthermore, we excluded 22 patients with missing genotype information and 2 patients with 11β-hydroxylase deficiency from all comparative analyses.
Results

General characteristics of the male CAH cohort
A total of 121 male patients were included in the CAH cohort in the dsd-LIFE study. General characteristics are shown in Table 1 . The median age of the study population was 28 years (IQR: 18.5-37.5, range We analyzed all variables mentioned in the 'Methods' section, but we only present in detail the data that differed between the analyzed groups (no overlap in the confidence intervals). In the following sections, we will present data regarding hormone concentrations, semen analysis and TART.
Hormone concentrations
Univariate descriptive analyses of hormone concentrations were performed. The proportion of patients with normal, decreased or increased serum testosterone, LH, FSH, inhibin B, AMH and SHBG concentrations is illustrated in Fig. 1A . Hormone concentrations were below the reference range in 19/97 (19.6%: testosterone), 8/43 (18.6%: inhibin B), 12/90 (13.3%: LH), 9/90 (10.0%: FSH) and 1/69 (1.4%: SHBG) of the participants. SHBG concentrations were above the reference range in 14.5% (10/69). Table 2 compares testosterone and gonadotropin concentrations in all patients with data on T, LH and FSH available. Seven patients (50%) with decreased testosterone concentrations had decreased gonadotropins, while 6 (42.9%) had normal LH and FSH concentrations and 1 (7.1%) patient had gonadotropin concentrations above reference range. Normal testosterone concentrations were found in 55/69 (79.7%) patients, 44 (80.0%) of whom had normal gonadotropin concentrations, whereas 7 (12.7%) had increased and 4 (7.3%) had decreased concentrations. Decreased testosterone concentrations were clearly associated with decreased LH and/or decreased FSH concentrations (OR: 12.8, 95% CI: 2.9-57.3).
A serum AD/TS ratio was calculated in 49 patients, 22 of whom (44.9%) had an AD/TS ratio ≥1. Ten patients (45.5%) with an AD/TS ≥1 had decreased gonadotropins, while 11 (50.0%) patients had normal gonadotropins and only 1 (4.5%) patient had increased gonadotropins. Normal AD/TS ratios were found in 27/49 (55.1%) patients, 21 of whom had normal gonadotropin concentrations (77.8%), 5 had increased concentrations, but none had decreased gonadotropin concentrations. An AD/TS ratio ≥1 was strongly associated with decreased LH and/or decreased FSH concentrations (OR: 39.3, 95% CI: 2.1-732.4).
Semen analysis
Semen analysis was performed in approximately one-third of the patients (Fig. 1B) . Normal values for all known (at least 3 out of 5) semen parameters (normozoospermia) were seen in 11/39 patients in whom semen analysis was performed. Sperm concentration, motility and volume were below the normal ranges in 38.5% (15/39), 35 .1% (13/37) and (Table 3 ). In only 2/10 patients with decreased testosterone, but normal gonadotropin concentrations, semen analysis was performed and both had decreased sperm concentrations (7.0 and 10.0 × 10 6 /mL). No statistically significant associations were found.
Testicular adrenal rest tumors
TARTs were visualized by ultrasound or MRI at crosssectional investigation in 28/68 patients. For 1 patient, the diagnosis was based on retrospective histology data. Furthermore, retrospective imaging data were available for 11 men: TARTs were present in 10 of these individuals.
In the total population screened, TARTs were present in 39 with TART reported to be present at age 16 years, TART was no longer observed during the cross-sectional investigation: one patient was misdiagnosed with TART as it appeared to be a varicocele, and in the other patient, TART (size 2 mm) disappeared after treatment with prednisone. This patient was still considered as a patient with TART in all analyses. when having a serum androstenedione concentration above the upper limit of normal at the time of the cross-sectional investigation was 3.6 (1.0-12.7). Similar associations were found for serum 17OHP at the crosssectional investigation, with an OR of 28.0 ( 3.1-252.5) for having TART when 17OHP concentrations were more than twice the upper level of the reference range and an OR of 18.7 (2.2-158.1) when these concentrations were above the reference range compared to concentrations within the reference range.
Comparison of patients with and without TART
Paternity
Data on paternity were available for 113 of the 121 patients, 26 (23.0%) of whom (age range 26-68 years) had fathered a total of 43 children. Three couples had used assisted reproductive techniques (ART) resulting in 4/43 children. One of the men who had used ART had decreased testosterone concentrations, while another had increased FSH, decreased sperm concentration and TART.
No information was available about the third patient who had used ART.
Discussion
This unique and relatively large European multicenter study shows that gonadal dysfunction is a common complication in male patients with CAH. Approximately half of the patients were affected by endocrine disturbances of the HPG axis at an adult age and TARTs were present in approximately half of the patients as well.
The difficulty in diagnosing hypogonadism in men with CAH is related to the fact that testosterone measured in serum is a mixture of testosterone of gonadal and adrenal origin (25, 28) . Circulating testosterone in male patients with well-controlled CAH is predominantly derived from testicular production, but when there is poor hormonal control, a relevant contribution arises from adrenal steroidogenesis. Until now, no method is able to discriminate between testosterone derived from the testes or the adrenal gland. Therefore, it has been suggested to use the serum AD/TS ratio in male patients with CAH, as this precursor steroid is elevated in serum when serum androgens are predominantly of adrenal origin (25) . Our data point toward an association between an AD/TS ratio Eight patients had decreased testosterone and gonadotropin concentrations, of which 5 provided semen samples. Semen analysis was performed and scored according to World Health Organization 2010 criteria (26): sperm concentration, motility, morphology and vitality, and semen volume were assessed. LRL, lower reference limit; n.d., not determined.
≥1 (testosterone mainly of adrenal origin) and decreased LH and/or decreased FSH concentrations, suggesting that adrenal androgens in men with CAH contribute to the suppression of gonadotropins. In approximately half of the patients, either aberrant testosterone or AD/TS ratios, or aberrant gonadotropin concentrations or a combination of both were found. In previous studies, the reported prevalence of endocrine HPG axis disturbances ranged from 20% to 52% (5, 6, 7, 9, 10) . However, only 1 other study provided information on testosterone and gonadotropin concentrations in each patient and also indicated hypogonadism in approximately half of the patients (6) . We recommend to include the evaluation of the AD/TS ratio in the regular follow-up of male patients with CAH and interpret this ratio in combination with gonadotropin concentrations in order to detect a disturbance of the HPG axis. Our study does not include data on 11-oxygenated androgens, that are generated through conversion of androstenedione and are reported to be elevated in patients with CAH (29, 30) .
Recent studies indicate that 11-oxygenated androgens are almost entirely derived from the 11beta-hydroxylation of androstenedione in the adrenal, and as they are potent androgens, they can contribute to suppression of the HPG axis (31) . However, their exact role in the evaluation of hormonal control and gonadal function in men with CAH has to be established in further studies. Serum AMH and inhibin B are also used as markers for male fertility (32) . However, it has been demonstrated that serum AMH concentrations do not correlate with sperm concentration and other male fertility parameters (33) . Serum inhibin B, a marker of Sertoli cell function, is known to correlate with spermatogenesis in healthy men (34) and was decreased in 18.6% of our cohort. Semen quality, assessed in one third of the study cohort, was reduced in 40% of the men. Except for the study of Urban and coworkers (3), all other studies on fertility in male patients with CAH showed decreased sperm concentrations ranging from 47.8% to 66% (4, 5, 6, 7, 9, 10) . More strikingly, in all studies, only half of the participants participated in semen analysis. Taken together, these data indicate the need for increased awareness on fertility status in patients with CAH and to start performing semen analysis and gonadal function biomarkers assessment from adolescence on, in order to detect disturbances early and allow semen preservation for later fertility purposes. Data from our cohort indicate, in agreement with previous studies (4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22) , that TART is a common complication in males with CAH (with a prevalence of 48.8%) and can have onset as early as in adolescence. In fact, 14 patients with TART at the time of the dsd-LIFE study already had TART at the age of 16 years. TARTs disappeared on treatment with prednisone in only 1 patient, thus indicating that complete regression of TART might only be achieved in a small proportion of the patients. Hence, prevention of the development of TART should be pursued, by optimizing treatment strategies already Table 4 Comparison of genetic and hormonal characteristics between patients with (n=33) and without testicular adrenal rest tumors (n=35). Odds ratios with 95% confidence intervals were calculated for many comparisons, but only odds ratios that clearly or potentially differ from unity are presented. Data are presented as number and percentage for each characteristic. in childhood. Current standard of care does not include imaging of testes; however, we recommend incorporating testicular ultrasound in routine clinical practice. In contrast to previous studies (4, 9, 10) , we observed an association between the CYP21A2 genotype and the presence of TARTs, with the prevalence of this complication being highest in men with the null CYP21A2 genotype. This supports the current perception that TARTs are more frequently observed in patients with a more severe form of CAH, as these patients are exposed to higher concentrations of ACTH, already in utero, which is thought to be a possible causative factor for TART development (6, 7, 15, 22) . However, a clinically relevant finding in this study is that TARTs occur even in less severe forms of 21OHD. In fact, in our study, 2 patients in genotype group C (both compound heterozygous for deletion and P30L mutation) had TARTs. In our current dataset, we could not find an association between genotype and semen quality or genotype and hypogonadism.
We found an association between increased 17OHP concentrations at cross-sectional data assessment and the presence of TART. Although a single 17OHP measurement may not be representative of overall metabolic control, these results could be interpreted as a possible indicator of the patient's metabolic control in the recent past. Therefore, our results seem to be in accordance with literature reporting higher TART prevalence in patients with poor hormonal control compared to patients with adequate hormonal control (5, 7, 13, 35, 36, 37, 38) . The association between increased androstenedione concentrations at cross-sectional data assessment and the presence of TARTs adds evidence to this pathophysiologic concept, even if the AD/T ratios were not clearly associated with TART within this subgroup of patients. Primary gonadal dysfunction may be suggested by raised FSH concentrations. In our dataset, 10 patients (11.1%) had elevated FSH concentrations. Seven of these patients had data on the presence of TART and 4 had evidence of TART. King and coworkers found that testicular failure was a consequence of TART in the majority of cases (10). However, our data are limited and do not allow firm conclusions concerning this issue.
Despite this being the first international multicenter study describing gonadal function in male patients with CAH, the study also has some limitations. All centers included in this consortium are tertiary care centers; therefore, it is possible that the patient groups were selected and that the patients included were more severely affected. Furthermore, serum hormone concentrations were not measured centrally, but in various centers, with a range of different assays. Accounting for this fact, only range variables were used in the data analyses. The median BMI in our patient cohort was 25.6 kg/m 2 (range: 22.0-29.2), which is slightly overweight. It has been demonstrated that excess of total and abdominal body fat could represent one cause of fertility impairment in men with CAH (25) . Serum total testosterone can be decreased in patients with obesity, as a result of the decreased serum concentration of SHBG. In case of increased serum SHBG (induced by hepatitis, hyperthyroidism or a genetic variant), total testosterone may be increased. Ideally, free testosterone should be measured in these cases, but this requires complex equilibrium dialysis (39) . Free testosterone can also be calculated from total testosterone, SHBG and albumin concentrations, but it is crucial that the results of such calculations are compared with the normal range of each separate laboratory. Such data were not available. We are aware that assessment of fertility by paternity numbers in our study was incomplete, as many other factors, including female fertility, were not available. Furthermore, participation in the medical examination was not compulsory for study inclusion. This may have led to even more selection, especially concerning the ultrasound examination and semen analysis. It is likely that only the very motivated patients and the more severely affected patients consented to these additional examinations. Due to the resulting low numbers of available data, multivariable logistic regression analyses were not possible.
In summary, impaired gonadal function is common in adult men with CAH. This is indicated by the presence of TART and/or hypogonadotropic or hypergonadotropic hypogonadism. The risk of TART is highest in men with the most severe enzyme deficiencies underlying CAH. Our data suggest that an association with poor previous hormonal control is likely but requires confirmation by prospective studies. Determination of the serum AD/TS ratio, in addition to serum concentrations of testosterone, androstenedione, LH and FSH may help to differentiate between testicular and adrenal androgens in male patients with CAH and to diagnose gonadal dysfunction. Routinely performed semen analysis, measurement of serum inhibin B and testicular ultrasound investigation already in adolescence are recommended to detect upcoming reproductive problems and to allow for fertility preserving measures, such as sperm banking.
